Clinical Pharmacology Study of NS-580 in Healthy female subjects (Phase I Study)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071220011

Enrollment

Registered

2022-05-27

Start date

2022-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Each subject receives a single oral dose of NS-580.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Provided written informed consent 2) Japanese female subjects 3) Body mass index (BMI) >=17.6 and <25.0 kg/m2 at the time of screening tests and hospitalization

Exclusion criteria

Exclusion criteria: 1) Sublects who are pregnant, may become pregnant, or wish to become pregnant during the trial period 2) Subjects who are breastfeeding 3) Subjects who have not confirmed a regular menstrual cycle at the time of screening test 4) Subjects who are irregular bleeding

Design outcomes

Primary

Measure	Time frame
PK parameters of NS-580 (AUC0-t and Cmax)	—

Contacts

Public ContactOperations Clinical

Nippon Shinyaku Co., Ltd.

zz_mail_clinical-trials@po.nippon-shinyaku.co.jp+81-120-40-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026